Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2020

View Archived Issues

Interleukins rile each other up in reaction to implants

Complement links high BMI to dementia

A novel prodrug strategy for enhancing the oral absorption of cephalosporin antibiotics

First-in-class TrxR inhibitor shows efficacy in an ovarian cancer mouse model

German approval for phase I/II trial of BNT-162 vaccine program to prevent COVID-19

CCL5 expression is regulated by two distinct enhancers during inflammation vs. homeostasis

Updates presented for phase II PASADENA study of prasinezumab

Phase II study of vixarelimab in prurigo nodularis meets primary efficacy endpoint

Positive data presented from phase III SPIRIT 2 study of relugolix combination therapy

Truncating DNVs in the last exon of SEMA6B causes progressive myoclonic epilepsy

Polymer-linked rotigotine shows promise in patients with PD

Cheating cell death improves post-infarct heart function

GRP78 does not predict bortezomib response in patients with multiple myeloma

Alpha Cognition signs up CRO to support development of Alpha-1062 for Alzheimer's

Takeda Pharmaceutical discloses new GIPR agonists

Antabio SAS divulges Pseudomonas aeruginosa elastase inhibitors

iTeos Therapeutics presents adenosine A2A receptor antagonists

Medshine Discovery identifies AOC3 inhibitors

New HBV HBeAg and HBsAg secretion inhibitors presented by Roche

FDA approves Trodelvy for previously treated metastatic TNBC

Oncorus enrolling in first-in-human trial of oncolytic immunotherapy ONCR-177

Amryt closes enrollment in phase III EASE trial of AP-101 for epidermolysis bullosa

Investigator-initiated trial to study Insmed's brensocatib for severe COVID-19

FDA clears IND for phase I trials of ImmuneOncia's IMC-002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...